Topics

Verseon Company Profile

22:31 EDT 21st September 2019 | BioPortfolio

Verseon is a technology-based pharmaceutical company that employs its proprietary computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. Verseon’s platform can consistently design novel drugs that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.


News Articles [7 Associated News Articles listed on BioPortfolio]

Verseon starts dosing in trial of VE-1902 to treat CAD

Verseon has started dosing in a Phase I clinical trial evaluating VE-1902 for the prevention of stroke and heart attack...Read More... The post Verseon starts dosing in trial of VE-1902 to treat CAD a...

Verseon begins dosing in phase 1 trial of VE-1902 oral anticoagulant

The early-stage trial will study safety, pharmacokinetics, and pharmacodynamics of VE-1902 in 100-120 participants. The blood thinner is the first PRrecision Oral AntiCoagulant (PROAC) of the US-based...

Verseon Pioneers New Way of Funding Innovation Through Security Token Offering

Verseon is launching a security token offering (STO) aiming to set a new standard for the 21st century public offering to a globally connected investor base. To make its ST...

Fintech Pioneer Blockrules to Launch One of the World’s First Prospectus-Backed Global Security Token Offerings for Pharma Company Verseon

BlockRules, the blockchain fintech company enforcing complex compliance rules directly on the blockchain, today announces that the first security token powered by its technology w...

Verseon Presents Oral Drug Candidate for Diabetic Eye Disease That Could Replace Eye Injections

One in three long-term diabetes patients will develop diabetic macular edema (DME), which can lead to blindness. Present DME treatments are recurring inj...

Verseon Presents Two Precision Oral Anticoagulants with Low Bleeding at International Stroke Conference

Technology-based pharma company Verseon presented two lead candidates from its new class of precision oral anticoagulants (PROACs) at last week’s International Stroke Con...

Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease Drugs

Oral drugs could provide a much-needed alternative to current eye injections One third of long-term diabetic patients are at risk of developing diabetic...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Verseon

Verseon is a technology-based pharmaceutical company that employs its proprietary computational drug discovery platform to develop novel therapeutics for today’s challenging ...

Verseon Corporation

Verseon Corporation (www.verseon.com, AIM: VSN) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, ...

More Information about "Verseon" on BioPortfolio

We have published hundreds of Verseon news stories on BioPortfolio along with dozens of Verseon Clinical Trials and PubMed Articles about Verseon for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Verseon Companies in our database. You can also find out about relevant Verseon Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record